CEF8, Influenza Virus NP (383-391), an influenza A virus nucleoprotein containing residues 383 to 391, is the most important HLA-B*2705-restricted epitope in the nucleoprotein of influenza A viruses and is associated with escape from cytotoxic T lymphocytes-mediated immunity.
CAT No: R1283
CAS No:142479-13-8
Synonyms/Alias:MK-2206 (dihydrochloride);142479-13-8;CEF8, Influenza Virus NP (383-391);NH2-Ser-Arg-Tyr-Trp-Ala-Ile-Arg-Thr-Arg-COOH;MK-2206 (2HCl);HY-P1835;AKOS040764030;DA-76166;HY-10358;TS-10397;CS-0096537;(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanamido]-3-(1H-indol-3-yl)propanamido]propanamido]-3-methylpentanamido]-5-carbamimidamidopentanamido]-3-hydroxybutanamido]-5-carbamimidamidopentanoic acid;
3. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function
5. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.